-
公开(公告)号：US08283163B2
公开(公告)日：2012-10-09
申请号：US12600103
申请日：2008-05-12
申请人： Makoto Inoue , Mamoru Hasegawa , Yoshikazu Yonemitsu , Yui Harada
发明人： Makoto Inoue , Mamoru Hasegawa , Yoshikazu Yonemitsu , Yui Harada
CPC分类号： C12N5/0639 , C12N2501/125 , C12N2501/22 , C12N2501/23 , C12N2501/26
摘要： The present invention provides methods for producing DCs, which comprise the step of culturing DC precursor cells in the presence of multiple cytokines, dendritic cells produced thereby, and uses thereof. The methods of the present invention enable production of large quantities of DC precursors with a high ability to differentiate into DCs. The present invention enables one to obtain large quantities of DCs from a small number of DC precursor cells, and therefore makes it easier to increase the number of DCs for administration in DC-based anti-tumor immunotherapy, treatment of infection, and such. Thus, an enhancement is expected for the effect of DC vaccines.
摘要翻译： 本发明提供了生产DC的方法，其包括在多种细胞因子存在下培养DC前体细胞的步骤，由此产生的树突状细胞及其用途。 本发明的方法能够生产具有高分化成DC的能力的大量DC前体。 本发明能够从少量的DC前体细胞获得大量的DC，因此能够更容易地增加DC-基抗肿瘤免疫治疗中的DC给药次数，感染治疗等。 因此，预期DC疫苗的效果将得到改善。
-
公开(公告)号：US20100184214A1
公开(公告)日：2010-07-22
申请号：US12600103
申请日：2008-05-12
申请人： Makoto Inoue , Mamoru Hasegawa , Yoshikazu Yonemitsu , Yui Harada
发明人： Makoto Inoue , Mamoru Hasegawa , Yoshikazu Yonemitsu , Yui Harada
CPC分类号： C12N5/0639 , C12N2501/125 , C12N2501/22 , C12N2501/23 , C12N2501/26
摘要： The present invention provides methods for producing DCs, which comprise the step of culturing DC precursor cells in the presence of multiple cytokines, dendritic cells produced thereby, and uses thereof. The methods of the present invention enable production of large quantities of DC precursors with a high ability to differentiate into DCs. The present invention enables one to obtain large quantities of DCs from a small number of DC precursor cells, and therefore makes it easier to increase the number of DCs for administration in DC-based anti-tumor immunotherapy, treatment of infection, and such. Thus, an enhancement is expected for the effect of DC vaccines.
摘要翻译： 本发明提供了生产DC的方法，其包括在多种细胞因子存在下培养DC前体细胞的步骤，由此产生的树突状细胞及其用途。 本发明的方法能够生产具有高分化成DC的能力的大量DC前体。 本发明能够从少量的DC前体细胞获得大量的DC，因此能够更容易地增加DC-基抗肿瘤免疫治疗中的DC给药次数，感染治疗等。 因此，预期DC疫苗的效果将得到改善。
-
3.发明申请Highly safe intranasally administrable gene vaccines for treating alzheimer's disease 审中-公开用于治疗阿尔茨海默氏病的高度安全的鼻内给药基因疫苗公开(公告)号：US20090170798A1
公开(公告)日：2009-07-02
申请号：US11918862
申请日：2006-04-20
申请人： Hideo Hara , Takeshi Tabira , Yoshikazu Yonemitsu , Makoto Inoue , Yumiko Tokusumi , Mamoru Hasegawa
发明人： Hideo Hara , Takeshi Tabira , Yoshikazu Yonemitsu , Makoto Inoue , Yumiko Tokusumi , Mamoru Hasegawa
IPC分类号： A61K31/7105 , C12N15/74 , A61P25/28
CPC分类号： C12N15/86 , A61K2039/5256 , A61K2039/543 , A61K2039/57 , C07K14/4711 , C12N2760/18843 , C12N2800/30
摘要： An objective of the present invention is to provide a safe and effective vaccine therapy for Alzheimer's disease. A minus strand RNA viral vector carrying amyloid gene was constructed, and administered intranasally to 24- to 25-months-old APP transgenic mice. The level of serum anti-A 42 antibody was determined and showed to be markedly higher than the control. The results of histological investigation showed that the administration of a vector of the present invention markedly reduced senile plaques in all of the frontal lobe, parietal lobe, and hippocampus. The brain A level was also markedly reduced. Furthermore, the administration of a vector of the present invention did not result in lymphocyte infiltration in the central nervous system.
摘要翻译： 本发明的目的是为阿尔茨海默病提供安全有效的疫苗疗法。 构建携带淀粉样蛋白基因的负链RNA病毒载体，鼻内给予24至25个月大的APP转基因小鼠。 测定血清抗-A42抗体水平，显示明显高于对照组。 组织学研究结果表明，施用本发明的载体显着降低了所有额叶，顶叶和海马中的老年斑。 脑A水平也明显降低。 此外，本发明的载体的施用不会导致中枢神经系统中的淋巴细胞浸润。
-
公开(公告)号：US08211868B2
公开(公告)日：2012-07-03
申请号：US13049011
申请日：2011-03-16
申请人： Yoshikazu Yonemitsu , Katsuo Sueishi , Masayuki Fukumura , Xiaogang Hou , Mamoru Hasegawa , Hidenori Matsusaka , Hiroyuki Tsutsui
发明人： Yoshikazu Yonemitsu , Katsuo Sueishi , Masayuki Fukumura , Xiaogang Hou , Mamoru Hasegawa , Hidenori Matsusaka , Hiroyuki Tsutsui
IPC分类号： A61K48/00
CPC分类号： C12N15/86 , A61K48/00 , C07K14/50 , C12N2760/18843 , C12N2800/30
摘要： The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.
摘要翻译： 本发明提供编码血管生成基因的副粘病毒载体及其用途。 使用副粘病毒载体能够有效地将血管生成基因转移到单个组织中。 FGF2基因在体内转移到缺血组织中诱导血管生成基因的表达而不引起水肿，并且防止由缺血引起的坏死。 本发明的载体适合于靶向缺血组织的基因治疗。
-
5.发明申请METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR 有权使用染色体非感染病毒载体生产复制细胞的方法公开(公告)号：US20110287538A1
公开(公告)日：2011-11-24
申请号：US13054022
申请日：2009-07-16
CPC分类号： C12N15/86 , C07K14/4702 , C12N5/0696 , C12N7/00 , C12N2501/60 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2510/00 , C12N2760/18622 , C12N2760/18643 , C12N2760/18645 , C12N2760/18662 , C12N2760/18822 , C12N2760/18843
摘要： An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.
摘要翻译： 本发明的目的是提供用于方便和有效地产生外源基因未整合到染色体中的ES样细胞的载体。 本发明人发现使用染色体非整合型病毒载体从体细胞产生ES样细胞的方法。 由于没有外源基因整合到产生的ES样细胞的染色体中，因此在测试和研究中是有利的，并且在疾病治疗中可以避免免疫排斥和伦理问题。
-
公开(公告)号：US20080199438A1
公开(公告)日：2008-08-21
申请号：US10598947
申请日：2005-03-15
IPC分类号： A61K48/00 , A61K31/7105 , A61K38/02 , A61P35/00
CPC分类号： A61K38/179 , C12N15/1136 , C12N2310/11 , C12N2310/14
摘要： The present invention provides methods for suppressing tumor proliferation comprising the step of inhibiting the expression of PDGF-A or the binding between PDGF-A homodimers and PDGFRα. Activation of the PDGFRα-p70S6K signal transduction pathway by PDGF-AA is an important factor in tumor angiogenesis and relates to the prognosis of patients suffering from tumors. By inhibiting PDGF-A expression in tumors or in their surrounding tissues, or by inhibiting the binding between PDGF-A homodimers and PDGFRα, the formation and retention of tumor vasculature can be inhibited, thereby suppressing tumor proliferation.
摘要翻译： 本发明提供了抑制肿瘤增殖的方法，包括抑制PDGF-A的表达或PDGF-A同源二聚体与PDGFRα之间的结合的步骤。 通过PDGF-AA激活PDGFRα-p70S6K信号转导途径是肿瘤血管生成中的重要因素，涉及肿瘤患者的预后。 通过抑制肿瘤或其周围组织中的PDGF-A表达，或通过抑制PDGF-A同源二聚体和PDGFRα之间的结合，可以抑制肿瘤血管的形成和保留，从而抑制肿瘤的增殖。
-
7.发明申请Anticancer Agent Containing Dendritic Cell Having Rna Virus Transferred Thereinto 有权含有转移Rna病毒的树突状细胞的抗癌剂公开(公告)号：US20080014183A1
公开(公告)日：2008-01-17
申请号：US11630532
申请日：2005-04-28
申请人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
发明人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
IPC分类号： A61K48/00
CPC分类号： A61K35/76 , A61K35/768 , A61K38/179 , A61K38/215 , A61K2039/5154 , C12N2760/18832 , C12N2760/18871
摘要： The present invention provides anticancer agents comprising dendritic cells introduced with RNA viruses. The present invention also provides methods for producing anticancer agents, which comprise the step of preparing dendritic cells introduced with RNA viruses. The present invention also provides methods for treating cancers using dendritic cells introduced with RNA viruses. The present invention provides effective methods for treating cancers, which use RNA viruses and dendritic cells in combination
摘要翻译： 本发明提供包含引入RNA病毒的树突状细胞的抗癌剂。 本发明还提供了制备抗癌剂的方法，其包括制备引入RNA病毒的树突状细胞的步骤。 本发明还提供了用RNA病毒引入的树突状细胞治疗癌症的方法。 本发明提供了组合使用RNA病毒和树突状细胞的治疗癌症的有效方法
-
公开(公告)号：US20080031855A1
公开(公告)日：2008-02-07
申请号：US11630522
申请日：2005-04-28
申请人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
发明人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
CPC分类号： A61K35/76 , A61K35/768 , A61K38/179 , A61K38/215 , A61K2039/5154 , C12N2760/18832 , C12N2760/18871
摘要： Minus-strand RNA viruses were found to have an effective tumor-suppressive effect even when they did not carry a therapeutically effective gene. The present invention provides anticancer agents comprising a minus-strand RNA virus. Furthermore, the present invention provides methods for producing the anticancer agents, which comprise the step of mixing a minus-strand RNA virus with pharmaceutically acceptable carriers. Furthermore, the present invention provides methods for suppressing cancer, which comprise the step of administering a minus-strand RNA virus to cancer tissues.
摘要翻译： 发现减数RNA病毒即使不携带治疗有效的基因也具有有效的肿瘤抑制作用。 本发明提供了包含负链RNA病毒的抗癌剂。 此外，本发明提供了制造抗癌剂的方法，其包括将负链RNA病毒与药学上可接受的载体混合的步骤。 此外，本发明提供了抑制癌症的方法，其包括向癌组织施用负链RNA病毒的步骤。
-
公开(公告)号：US20070269414A1
公开(公告)日：2007-11-22
申请号：US10578085
申请日：2004-10-29
CPC分类号： C12N15/86 , A61K2039/5156 , C12N2510/02 , C12N2760/18843
摘要： The present invention provides a method for introducing a gene into a dendritic cell, which includes the step of contacting a minus-strand RNA virus with a dendritic cell. The present invention also provides a method for producing a gene transferred dendritic cell, which includes the step of contacting a minus-strand RNA virus with a dendritic cell. The present invention also provides gene transferred dendritic cells produced by such methods. Furthermore, the present invention provides a method for activating a dendritic cell, which includes the step of contacting a minus-strand RNA virus with a dendritic cell. The present invention enables efficient gene delivery into dendritic cells. Dendritic cells introduced with antigen gene or cytokine gene are useful as vaccine.
摘要翻译： 本发明提供了将基因导入树状细胞的方法，其包括使负链RNA病毒与树突状细胞接触的步骤。 本发明还提供了一种转基因树突状细胞的制备方法，其包括将负链RNA病毒与树突状细胞接触的步骤。 本发明还提供了通过这些方法产生的基因转移的树突状细胞。 此外，本发明提供了激活树突细胞的方法，其包括使负链RNA病毒与树突状细胞接触的步骤。 本发明使得有效的基因递送到树突状细胞中。 引入抗原基因或细胞因子基因的树突状细胞可用作疫苗。
-
10.发明申请公开(公告)号：US20070173466A1
公开(公告)日：2007-07-26
申请号：US10549474
申请日：2004-03-05
IPC分类号： A61K31/7105
CPC分类号： A61K31/7088 , A61K38/00 , C07K14/4703
摘要： The present invention relates to methods for treating inflammatory diseases accompanied by bone destruction, comprising the step of administering a viral vector comprising a gene which inhibits signal transduction mediated by fibroblast growth factor-2 (FGF2)-FGF receptor 1-Ras-Raf-MAP kinase to a diseased region. Furthermore, the present invention relates to therapeutic compositions for inflammatory diseases accompanied by bone destruction, which comprise these vectors. By inhibiting FGF2 signal transduction through local administration of viral vectors, both inflammation and bone destruction in inflammatory bone destruction were simultaneously suppressed. The present invention provides disease-specific and effective therapeutic methods, and therapeutic compositions for inflammatory diseases such as osteoarthritis, for which therapy has so far been difficult.
摘要翻译： 本发明涉及用于治疗伴随骨破坏的炎性疾病的方法，其包括施用包含抑制由成纤维细胞生长因子-2（FGF2）-FGF受体1-Ras-Raf-MAP介导的信号转导的基因的病毒载体的步骤 激酶到病变区域。 此外，本发明涉及包含这些载体的伴随骨破坏的炎性疾病的治疗组合物。 通过局部施用病毒载体抑制FGF2信号转导，同时抑制炎性骨破坏中的炎症和骨破坏。 本发明提供疾病特异性和有效的治疗方法，以及用于迄今难以治疗的炎性疾病如骨关节炎的治疗组合物。
-
-
-
-
-
-
-
-
-
搜索结果
143 条记录 (耗时 0.037 秒)
